Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
NCT Number: NCT07456332
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease in people living with HIV (PLWH). Currently, there are no approved medications to treat this condition. That's why weight loss through healthy lifestyle changes is the most important way to manage it.
This study will test if a digital nutritional program (DNP), using a mobile phone app, can help improve weight loss better than the usual advice on healthy eating and exercise.
The study includes people living with HIV, aged 18 and older, with fatty liver (detected by ultrasound or other scans), and on stable HIV treatment.
Participants will be randomly assigned to two groups:
* Intervention group: Will receive personalized lifestyle support through a mobile app (DNP). * Control group: Will receive general advice on healthy habits. The study will last 12 months, with follow-up visits during and after the program.
What Will Be Measured:
* Weight, waist size, blood pressure, and body fat. * Blood tests to check cholesterol, sugar levels, liver enzymes, and other markers. * Liver scans to assess fat and stiffness. * Questionnaires on eating habits, exercise, and satisfaction with the program.
Goals of the Study:
Main goal: To see how many people lose at least 5% of their body weight after 6 months.
Other goals: To see the effects on weight after 12 months, and 6 months after stopping the program, and to monitor improvements in liver health.
Why This Matters:
This study aims to find new ways to help people with HIV improve their liver health and overall well-being through simple, practical tools like a mobile app.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Advice on healthy lifestyle recommendations given by a trained physician or nurse, based on a Mediterranean diet (based on fruits, vegetables, legumes, whole grains, fish or white meat and olive oil; avoid processed foods, red meat and sugary drinks). Delivery of written resources containing healthy eating guidelines and advice.
Time frame: From enrollment to month 6
Percentage of body weight change=( baseline body weight-6 month body weight/baseline body weight)×100.
We will compare the percentage of participants who achieve a body weight reduction of ≥ 5% between the two arms, at month 6.
Time frame: From enrollment to month 12
Percentage of body weight change=( Baseline body weight-6 month body weight/baseline body weight)×100.
We will compare the percentage of participants who achieve a body weight reduction of ≥ 5% between the two arms, at month 12.
Time frame: From month 12 to month 6 after Digital Nutritional Program discontinuation.
To compare body weight between month 12 and month 6 after Digital Nutritional Program discontinuation.
Time frame: From enrollment to month 12
Liver steatosis will be assessed using the Controlled Attenuation Parameter obtained by transient elastography, with a cutoff value of 275 dB/m used to define liver steatosis.
Time frame: From enrollment to month 12
Liver stiffness will be assessed by transient elastography, with a cutoff value of 8-12 kPa may be associated with fibrosis and > 12 kPa is associated with a high likelihood of advanced fibrosis
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Total cholesterol measured in mg/dL
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Low-density lipoprotein cholesterol measured in mg/dL
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
High-density lipoprotein cholesterol measured in mg/dL
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Tryglicerides measured in mg/dL
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Glucose measured in mg/dL
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Insulin measured in pmol/L
Time frame: Time Frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Liver enzimes include: alanine transaminase, aspartete transaminase and gamma-glutamyl transferase measured in U/L
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
The mean of two measures at the narrowest point between the lower costal border and the iliac crest during expiration using a tape measure.
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Body composition will be measured using a bioelectrical impedance analyzer. Fat mass in Kg and percentage of total body mass will be recorded.
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Skeletal muscle mass will be measured using a bioelectrical impedance analyzer.
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
Body lean mass will be measured using a bioelectrical impedance analyzer.
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation.
To assess dietary habits Mediterranean Diet Adherence Questionnaire will be used. The questionnaire includes key dietary components (fruits, vegetables, legumes, fish, olive oil, meats, beverages). Each item is scored according to the scale criteria. Minimum value 0, maximum value 14. Higher scores indicate greater adherence. A score above 10 indicates good adherence to the Mediterranean diet. A score <7 indicates low adherence.
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation
To assess physical activity we use Physical Activity Questionnaire-Short Form. The IPAQ-SF is a 7-item questionnaire designed to estimate the frequency and duration of physical activity performed during the previous 7 days.
The questionnaire assesses three intensity levels of activity:
Unit: Metabolic Equivalent Task minutes per week (MET-minutes/week):
Time frame: Data are assessed at 6 and 12 months
Data to evaluate adherence will by recorded by the digital program based on the participant's usage. A patient is considered adherent if he has been accessing the program for a minimum period of 30 calendar days in 6 months.
Time frame: From enrollment to month 6, 12 and 6 after Digital Nutritional Program discontinuation
To assess health-related quality of life we use the Euro quality of life 5 dimensions (EuroQoL-5D) health questionnaire. This self-reported instrument evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Three dimension level is used. Responses across the five dimensions were converted into a utility index using population value sets, ranging from values below 0 (health states worse than death) to 1 (perfect health).
Hospital Universitari de Bellvitge
Other
Acronym: APEVI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06944353
Digestive System Diseases, Fatty Liver
Chicago, Illinois, United States
View Trial DetailsNCT06703450
Metabolic Dysfunction-Associated Steatotic Liver Disease
New York, United States
View Trial DetailsNCT06986447
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Chandler, Arizona, United States
View Trial DetailsNCT06994871
Metabolic Dysfunction-Associated Steatotic Liver Disease
Nanjing, Jiangsu, China
View Trial Details